Breast Cancer Clinical Trial
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
Summary
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Full Description
OUTLINE: This is a multi-center study.
Sample Collection:
Tumor sample
Serum sample
Treatment Regimen:
All registered patients must be planning treatment with lonafarnib
Eligibility Criteria
Inclusion Criteria:
Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
Age > 18 years.
Planned treatment with lonafarnib for metastatic breast cancer.
Must consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study.
Exclusion Criteria:
Planned treatment with any other treatment regimen
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Indianapolis Indiana, 46202, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.